No significant impact of patient age and prior treatment profile with docetaxel on the efficacy of cabazitaxel in patient with castration-resistant prostate cancer.

Abstract:

BACKGROUND:The correlation of the oncological outcomes of docetaxel and cabazitaxel in Japanese metastatic castration-resistant prostate cancer (mCRPC) patients has not been unclear. MATERIALS AND METHODS:This study included a total of 47 consecutive Japanese mCRPC patients treated with cabazitaxel and assessed the prognostic significance of cabazitaxel, focusing on patient age and the correlation of efficacy between docetaxel and cabazitaxel. RESULTS:Prostate-specific antigen (PSA) decline was observed in 27 patients (57.4%), including 19 (40.0%) achieving the response defined by PSA decline ≥ 30%. The median overall survival (OS) periods after the introduction of cabazitaxel was 16.1 months. Twenty (42.6%) were judged to have responded to cabazitaxel with a PSA decrease ≥ 30% from the baseline. A 30% PSA response to cabazitaxel was achieved in 4 (50.0%) patients with ≧ 75 years (n = 8) and 16 (41.0%) patients with less than 75 years (n = 39). There was no significant correlation between the PSA response and patients' age (p = 0.707). A 30% PSA response to cabazitaxel was achieved in 13 (46.4%) and 7 (36.8%) patients with and without that to docetaxel, respectively. A 30% PSA response to cabazitaxel was achieved in 5 (16.6%) and 7 (41.2%) patients who had treated with less than 10 cycles docetaxel or 10 ≦ cycles, respectively. Univariate and multivariate analyses revealed that there were no significant correlation of patient age (p = 0.537), the response to prior docetaxel therapy (p = 0.339) or cycles of docetaxel therapy (p = 0.379) with shorter OS. CONCLUSION:These results indicate that the introduction of cabazitaxel for Japanese mCRPC patients could result in oncological outcomes without any association with patient's age and the profiles of previous docetaxel therapy.

authors

Kosaka T,Hongo H,Watanabe K,Mizuno R,Kikuchi E,Oya M

doi

10.1007/s00280-018-3698-1

subject

Has Abstract

pub_date

2018-12-01 00:00:00

pages

1061-1066

issue

6

eissn

0344-5704

issn

1432-0843

pii

10.1007/s00280-018-3698-1

journal_volume

82

pub_type

杂志文章
  • Effect of mitomycin C, verapamil, and hyperthermia on human gastric adenocarcinoma.

    abstract::The purpose of this study was to assess the efficacy of verapamil (20 microM) and hyperthermia (42 degrees C) as modifiers of mitomycin C (MMC), used at different concentrations, in inhibiting the growth of human gastric adenocarcinoma (AGS) cells. Combined verapamil and hyperthermia treatment resulted in a significan...

    journal_title:Cancer chemotherapy and pharmacology

    pub_type: 杂志文章

    doi:10.1007/BF00685086

    authors: Shchepotin IB,Buras RR,Nauta RJ,Shabahang M,Evans SR

    更新日期:1994-01-01 00:00:00

  • Prevention of doxorubicin-induced cardiomyopathy by reduced glutathione.

    abstract::The aim of the present investigation was to evaluate the potential cardioprotective effect of reduced glutathione (GSH) against the delayed cardiomyopathy induced by doxorubicin (DXR) in a well-documented rat model. DXR was administered i.v. at a weekly dose of 3 mg/kg for a total of 4 doses; 250 or 500 mg/kg of GSH w...

    journal_title:Cancer chemotherapy and pharmacology

    pub_type: 杂志文章

    doi:10.1007/BF00685691

    authors: Villani F,Galimberti M,Zunino F,Monti E,Rozza A,Lanza E,Favalli L,Poggi P

    更新日期:1991-01-01 00:00:00

  • In vitro effect of r-verapamil on acute myelogenous leukemia blast cells: studies of cytokine secretion and cytokine-dependent blast proliferation.

    abstract::The in vitro effect of the dextroisomer r-verapamil on blast cells derived from patients with acute myelogenous leukemia (AML) was studied. R-verapamil caused a dose-dependent inhibition of AML blast proliferation in the presence of stem-cell factor, leukemia inhibitory factor, interleukin 4, interleukin 6, and interl...

    journal_title:Cancer chemotherapy and pharmacology

    pub_type: 杂志文章

    doi:10.1007/BF00685631

    authors: Bruserud O,Nesthus I,Pawelec G

    更新日期:1995-01-01 00:00:00

  • Erratum to: Docetaxel, cisplatin, and fluorouracil combination in neoadjuvant setting in the treatment of locally advanced gastric adenocarcinoma: Phase II NEOTAX study.

    abstract::Erratum to: Cancer Chemother Pharmacol (2014), 74:1139–1147, DOI 10.1007/s00280‑014‑2586‑6. Unfortunately, the part of acknowledgement detail was omitted in the published article and the below line must be considered as the last sentence: "This study is a Turkish Oncology Group trial". ...

    journal_title:Cancer chemotherapy and pharmacology

    pub_type: 已发布勘误

    doi:10.1007/s00280-015-2797-5

    authors: Ozdemir N,Abali H,Vural M,Yalcin S,Oksuzoglu B,Civelek B,Oguz D,Bostanci B,Yalcin B,Zengin N

    更新日期:2015-07-01 00:00:00

  • Phase I dose-finding and pharmacokinetic study of the oral epidermal growth factor receptor tyrosine kinase inhibitor Ro50-8231 (erlotinib) in Japanese patients with solid tumors.

    abstract:PURPOSE:The objectives of this phase I dose-finding study of erlotinib were to investigate the toxicity profile, to confirm the acceptable toxicity of doses up to 150 mg/day, and to assess the pharmacokinetic (PK) profile and antitumor activity in Japanese patients with solid tumors. PATIENTS AND METHODS:Patients with...

    journal_title:Cancer chemotherapy and pharmacology

    pub_type: 杂志文章

    doi:10.1007/s00280-007-0494-8

    authors: Yamamoto N,Horiike A,Fujisaka Y,Murakami H,Shimoyama T,Yamada Y,Tamura T

    更新日期:2008-03-01 00:00:00

  • Comparison of the potency of glycosylated and nonglycosylated recombinant human granulocyte colony-stimulating factors in neutropenic and nonneutropenic CD rats.

    abstract::Recent studies in human bone-marrow culture and healthy human volunteers suggest that lenograstim [glycosylated, recombinant human granulocyte colony-stimulating factor (rHuG-CSF) produced in Chinese hamster ovary (CHO) cells] has greater in vivo potency than filgrastim [nonglycosylated, methionine-extended recombinan...

    journal_title:Cancer chemotherapy and pharmacology

    pub_type: 杂志文章

    doi:10.1007/s002800050570

    authors: Nohynek GJ,Plard JP,Wells MY,Zerial A,Roquet F

    更新日期:1997-01-01 00:00:00

  • Pegylated liposomal doxorubicin, 5-fluorouracil and cisplatin versus mitomycin-C, 5-fluorouracil and cisplatin for advanced gastric cancer: a randomized phase II trial.

    abstract:PURPOSE:Clinical data suggested that a regimen incorporating doxorubicin to 5-fluorouracil (5-FU) and cisplatin may be more effective but probably quite toxic for advanced gastric cancer patients. With the aim to maintain efficacy while reducing toxicity, we compared the activity and safety of a combination of 5-FU, ci...

    journal_title:Cancer chemotherapy and pharmacology

    pub_type: 杂志文章,多中心研究,随机对照试验

    doi:10.1007/s00280-010-1424-8

    authors: Cascinu S,Galizia E,Labianca R,Ferraù F,Pucci F,Silva RR,Luppi G,Beretta GD,Berardi R,Scartozzi M

    更新日期:2011-07-01 00:00:00

  • Chemomodulation of drugs involved in multidrug resistance in chronic lymphatic leukemia of the B-cell type.

    abstract::Reduced drug accumulation may be one reason for intrinsic drug resistance in chronic lymphatic leukemia of the B-cell type (B-CLL). Immunophenotyped leukemic human B-cells from 38 cases of B-CLL were characterized for P-glycoprotein (PGP) content. In all, 30 cases of B-CLL were additionally analyzed for further parame...

    journal_title:Cancer chemotherapy and pharmacology

    pub_type: 杂志文章

    doi:10.1007/BF00686038

    authors: Reichle A,Diddens H,Altmayr F,Rastetter J,Andreesen R

    更新日期:1994-01-01 00:00:00

  • Phase I and pharmacokinetic study of nab-paclitaxel, nanoparticle albumin-bound paclitaxel, administered weekly to Japanese patients with solid tumors and metastatic breast cancer.

    abstract:PURPOSE:We conducted phase I and tolerability studies to determine the maximum tolerated dose (MTD) and recommended dose of nab-paclitaxel when administered weekly with solid tumors and to evaluate the tolerability of weekly administration at a dose of 150 mg/m(2) with metastatic breast cancer (MBC) as a first-line the...

    journal_title:Cancer chemotherapy and pharmacology

    pub_type: 杂志文章

    doi:10.1007/s00280-011-1726-5

    authors: Ando M,Yonemori K,Katsumata N,Shimizu C,Hirata T,Yamamoto H,Hashimoto K,Yunokawa M,Tamura K,Fujiwara Y

    更新日期:2012-02-01 00:00:00

  • Cytochrome P450 isozymes 3A4 and 2B6 are involved in the in vitro human metabolism of thiotepa to TEPA.

    abstract:PURPOSE:To establish the cytochrome P450 (CYP) isozymes involved in the metabolism of the alkylating agent, thiotepa, to the pharmacologically active metabolite, TEPA. METHODS:In vitro chemical inhibition studies were conducted by incubating thiotepa and pooled human hepatic microsomes in the presence of known inhibit...

    journal_title:Cancer chemotherapy and pharmacology

    pub_type: 杂志文章

    doi:10.1007/s00280-002-0453-3

    authors: Jacobson PA,Green K,Birnbaum A,Remmel RP

    更新日期:2002-06-01 00:00:00

  • New natural products of interest under development at the National Cancer Institute.

    abstract::Fourteen new agents of natural products origin which are under development as antitumor agents at the National Cancer Institute are discussed with reference to their sources, structures, antitumor activity, current status, and future prospects as clinically effective agents. ...

    journal_title:Cancer chemotherapy and pharmacology

    pub_type: 杂志文章

    doi:10.1007/BF00254042

    authors: Douros J,Suffness M

    更新日期:1978-01-01 00:00:00

  • Further characterization of the sixth transmembrane domain of Pgp1 by site-directed mutagenesis.

    abstract:PURPOSE:Several studies have identified amino acid residues located on the hydrophobic side of the helix that forms transmembrane domain 6 (TM6) of the ABC transporter P-glycoprotein (Pgp) as being important for function. The purpose of this study was to determine if alterations to residues on the hydrophilic side coul...

    journal_title:Cancer chemotherapy and pharmacology

    pub_type: 杂志文章

    doi:10.1007/s002800100354

    authors: Song J,Melera PW

    更新日期:2001-11-01 00:00:00

  • Experience with 24-h infusions of ifosfamide/mesna in small cell lung cancer.

    abstract::Two studies were carried out (A and B) in order to assess the effectiveness of ifosfamide administered with mesna (IFO/M) in the treatment of small cell lung cancer. The first study (A) was a cross-over study; the second (B) was a randomized trial, and in B IFO/M was evaluated earlier in the course of the disease. IFO...

    journal_title:Cancer chemotherapy and pharmacology

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1007/BF00647447

    authors: Cantwell BM,Harris AL,Bozzino JM

    更新日期:1986-01-01 00:00:00

  • Antagonism of oestrogen action in human breast and endometrial cells in vitro: potential novel antitumour agents.

    abstract:PURPOSE:There is a need to find novel oestrogen receptor (ER) ligands that antagonize oestrogen action in the reproductive tissues and would therefore have therapeutic potential in oestrogen-dependent tumours. We tested novel ER ligands in both breast and endometrial cells to profile agonism/antagonism in these oestrog...

    journal_title:Cancer chemotherapy and pharmacology

    pub_type: 杂志文章

    doi:10.1007/s002800000259

    authors: Nuttall ME,Pendrak I,Emery JG,Nadeau DP,Fisher PW,Nicholson TA,Zhu Y,Suva LJ,Kingsbury WD,Gowen M

    更新日期:2001-05-01 00:00:00

  • Cellular pharmacology of N4-hexadecyl-1-beta-D-arabinofuranosylcytosine in the human leukemic cell lines K-562 and U-937.

    abstract::The mechanisms of cytotoxicity, cellular drug uptake, intracellular drug distribution, cellular pharmacokinetics, formation of arabinofuranosylcytosine triphosphate (ara-CTP), and DNA incorporation of N4-hexadecyl-1-beta-D-arabinofuranosylcytosine (NHAC), a new lipophilic derivative of arabinofuranosylcytosine (ara-C)...

    journal_title:Cancer chemotherapy and pharmacology

    pub_type: 杂志文章

    doi:10.1007/BF00685798

    authors: Horber DH,Schott H,Schwendener RA

    更新日期:1995-01-01 00:00:00

  • Antitumor activity of interleukin 12 in preclinical models.

    abstract::Interleukin 12 (IL-12) is a heterodimeric cytokine with a number of biological effects that are consistent with its potential role as an antitumor agent. The antimetastatic and antitumor activities of IL-12 have been demonstrated in a number of murine tumor models. Both the inhibition of established experimental pulmo...

    journal_title:Cancer chemotherapy and pharmacology

    pub_type: 杂志文章,评审

    doi:10.1007/s002800051031

    authors: Brunda MJ,Luistro L,Rumennik L,Wright RB,Dvorozniak M,Aglione A,Wigginton JM,Wiltrout RH,Hendrzak JA,Palleroni AV

    更新日期:1996-01-01 00:00:00

  • Comparative intraperitoneal pharmacokinetics of three platinum analogues.

    abstract::The pharmakokinetic profiles of intraperitoneally infused platinum analogues were determined in 13 women exhibiting minimal residual disease following surgery and systemic chemotherapy for epithelial ovarian cancer or fallopian tube carcinoma by following the disposition of tracer doses of 195mPt radiolabel. Six patie...

    journal_title:Cancer chemotherapy and pharmacology

    pub_type: 杂志文章

    doi:10.1007/BF00685543

    authors: Lind MJ,Murphy DJ,Sharma H,Tinker N,Smith A,McAuliffe CA,Crowther D

    更新日期:1991-01-01 00:00:00

  • Lack of in vivo cross-resistance with 4'-thio-ara-C against drug-resistant murine P388 and L1210 leukemias.

    abstract:PURPOSE:4'-Thio-β-D-arabinofuranosylcytosine (4'-thio-ara-C), which has shown a broad spectrum of antitumor activity against human tumor systems in mice and is undergoing clinical trials, was evaluated for cross-resistance to seven clinical agents in order to identify potentially useful guides for patient selection for...

    journal_title:Cancer chemotherapy and pharmacology

    pub_type: 杂志文章

    doi:10.1007/s00280-010-1498-3

    authors: Waud WR,Gilbert KS,Secrist JA 3rd

    更新日期:2011-08-01 00:00:00

  • Effects of elotuzumab on QT interval and cardiac safety in patients with multiple myeloma.

    abstract:PURPOSE:To assess the effect of elotuzumab on corrected QT (QTc) intervals and cardiac safety. METHODS:Patients with high-risk smoldering multiple myeloma who had been treated with elotuzumab monotherapy (10 or 20 mg/kg) in Study CA204011 (NCT01441973) underwent electrocardiogram (ECG) examination over 8-10 weeks (tre...

    journal_title:Cancer chemotherapy and pharmacology

    pub_type: 杂志文章

    doi:10.1007/s00280-016-3182-8

    authors: Passey C,Darbenzio R,Jou YM,Lynch M,Gupta M

    更新日期:2016-12-01 00:00:00

  • A phase II study of human rDNA alpha-2 interferon in patients with low grade non-Hodgkin's lymphoma.

    abstract::Thirty-five patients with a diagnosis of non-Hodgkin's lymphoma of low histological grade were treated with 2 X 10(6)/m2 of human rDNA alpha 2 IFN-a2 by subcutaneous injection. Treatment was continued until progressive disease was documented or one year of therapy had been given. None of the patients had to stop treat...

    journal_title:Cancer chemotherapy and pharmacology

    pub_type: 杂志文章

    doi:10.1007/BF00253065

    authors: Wagstaff J,Loynds P,Crowther D

    更新日期:1986-01-01 00:00:00

  • Evaluation of gefitinib efficacy according to body mass index, body surface area, and body weight in patients with EGFR-mutated advanced non-small cell lung cancer.

    abstract:PURPOSE:In patients with epidermal growth factor receptor (EGFR)-mutated, advanced, non-small cell lung cancer (NSCLC), common gefitinib-sensitive EGFR mutations that predict a greater response to therapy include the exon 19 deletion and L858R point mutation. The objective of this study was to evaluate whether body sur...

    journal_title:Cancer chemotherapy and pharmacology

    pub_type: 杂志文章

    doi:10.1007/s00280-016-3232-2

    authors: Imai H,Kuwako T,Kaira K,Masuda T,Miura Y,Seki K,Sakurai R,Utsugi M,Shimizu K,Sunaga N,Tomizawa Y,Ishihara S,Ishizuka T,Mogi A,Hisada T,Minato K,Takise A,Saito R,Yamada M

    更新日期:2017-03-01 00:00:00

  • Effect of cyclosporine on colchicine partitioning in the rat liver.

    abstract::Colchicine is secreted into bile as a major pathway of elimination. Cyclosporine (CsA) inhibits colchicine biliary secretion. In the present study, the effects of cyclosporine and its vehicle (cremophor) on the partitioning of colchicine across the liver were studied. CsA decreased the colchicine bile/plasma ratio fro...

    journal_title:Cancer chemotherapy and pharmacology

    pub_type: 杂志文章

    doi:10.1007/BF00685886

    authors: Speeg KV,Maldonado AL

    更新日期:1993-01-01 00:00:00

  • ABT-263 sensitizes TRAIL-resistant hepatocarcinoma cells by downregulating the Bcl-2 family of anti-apoptotic protein.

    abstract:PURPOSE:Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) is a promising anticancer agent due to its selective cytotoxicity to transformed cells. However, most human hepatocellular carcinomas (HCC) develop resistance to TRAIL. Thus, there is an urgent need to investigate the molecular targets and the unde...

    journal_title:Cancer chemotherapy and pharmacology

    pub_type: 杂志文章

    doi:10.1007/s00280-011-1763-0

    authors: Wang G,Zhan Y,Wang H,Li W

    更新日期:2012-03-01 00:00:00

  • Evodiamine inhibits the migration and invasion of nasopharyngeal carcinoma cells in vitro via repressing MMP-2 expression.

    abstract:PURPOSE:Evodiamine is one of active alkaloids isolated from the traditional Chinese medicine Evodia rutaecarpa Bentham and has various pharmacological properties. In this study, we investigated its effects on the migration, invasion, and associated mechanism in human nasopharyngeal carcinoma (NPC) cells. METHODS:Cell ...

    journal_title:Cancer chemotherapy and pharmacology

    pub_type: 杂志文章

    doi:10.1007/s00280-015-2902-9

    authors: Peng X,Zhang Q,Zeng Y,Li J,Wang L,Ai P

    更新日期:2015-12-01 00:00:00

  • Phase II trial of idarubicin in patients with advanced lymphoma.

    abstract::A phase II trial of idarubicin was performed in 24 patients with advanced lymphoma. The drug was administered in a dose of 10-15 mg/m2 i.v. or 15-70 mg/m2 p.o. (single dose) every 3 weeks. There were four partial responses and four minor responses. All but one of the responders had received prior doxorubicin therapy. ...

    journal_title:Cancer chemotherapy and pharmacology

    pub_type: 杂志文章

    doi:10.1007/BF00262782

    authors: Gillies H,Liang R,Rogers H,Harper P,Parapia L,Cox G,Johnson S

    更新日期:1988-01-01 00:00:00

  • Phase I clinical trial f mitoxantrone: a new anthracenedione anticancer drug.

    abstract::Mitoxantrone, 1,4-dihydroxy-5,8-bis(((2-[(2-hydroxyethyl)amino]ethyl) amino))-9,10-anthracenedione dihydrochloride, a new antitumor agent was evaluated in nine cancer patients as part of a phase I trial. In general, the drug was well tolerated. Leukopenia was the dose-limiting toxic effect. Mild to moderate leukopenia...

    journal_title:Cancer chemotherapy and pharmacology

    pub_type: 杂志文章

    doi:10.1007/BF00578556

    authors: Alberts DS,Griffith KS,Goodman GE,Herman TS,Murray E

    更新日期:1980-01-01 00:00:00

  • Citrate enhances the protective effect of orally administered bismuth subnitrate against the nephrotoxicity of cis-diamminedichloroplatinum.

    abstract::Attenuation of the renal toxicity of cis-diamminedichloroplatinum (CDDP) is important in the use of this effective but cytotoxic anticancer agent. We have previously shown that the renal toxicity of CDDP can be efficiently reduced by the induction of metallothionein (MT) by preadministration of bismuth compounds in mi...

    journal_title:Cancer chemotherapy and pharmacology

    pub_type: 杂志文章

    doi:10.1007/s00280-003-0706-9

    authors: Kondo Y,Himeno S,Satoh M,Naganuma A,Nishimura T,Imura N

    更新日期:2004-01-01 00:00:00

  • Intracellular activation and cytotoxic action of RS-1541 against cultured human tumor cells.

    abstract::RS-1541, an acyl-derivative of rhizoxin (Fig. 1), is a potent antitumor compound. This agent showed cytotoxicity in vitro on some cultured human tumor cells, although it was less potent than rhizoxin. Rhizoxin exhibited antitumor effects by inhibiting the polymerization of tubulin, whereas RS-1541 did not inhibit tubu...

    journal_title:Cancer chemotherapy and pharmacology

    pub_type: 杂志文章

    doi:10.1007/BF00689446

    authors: Takatori T,Koizumi T,Tokui T,Mitsuhashi Y,Shiraishi A,Tsuruo T

    更新日期:1995-01-01 00:00:00

  • Pharmacokinetics of neamine in rats and anti-cervical cancer activity in vitro and in vivo.

    abstract:OBJECTIVE:To study the pharmacokinetics of neamine in rats and to evaluate its anti-cervical cancer activity. METHODS:The plasma level of neamine was determined by HPLC-ELSD. Pharmacokinetic parameters were calculated using DAS 2.0 software. Tissue microarray analysis was conducted to examine angiogenin (ANG) expressi...

    journal_title:Cancer chemotherapy and pharmacology

    pub_type: 杂志文章

    doi:10.1007/s00280-014-2658-7

    authors: Liu Y,Zhang X,An S,Wu Y,Hu G,Wu Y

    更新日期:2015-03-01 00:00:00

  • Metronomics chemotherapy: time for computational decision support.

    abstract::Over the last decade, metronomic chemotherapy has been increasingly considered as an attractive strategy for treating cancer in a variety of settings. Beside pharmaco-economic considerations making metronomics a unique opportunity in low- or middle-income countries, revisiting dosing schedules using continuous low dos...

    journal_title:Cancer chemotherapy and pharmacology

    pub_type: 杂志文章,评审

    doi:10.1007/s00280-014-2546-1

    authors: Barbolosi D,Ciccolini J,Meille C,Elharrar X,Faivre C,Lacarelle B,André N,Barlesi F

    更新日期:2014-09-01 00:00:00